TGF-β1 blockade by different approaches, including neutralizing antibodies, siRNAs, or blockers such as decorin, inhibited fibrosis both in vitro and in experimental renal disease [40, 50–53]. This evidence concerns the gene TGFB1 and kidney disorder.